Posted on April 18, 2022 by Sitemaster
This coming Friday, April 22, at 11:00 am Eastern / 8 am Pacific, there will be an important new educational opportunity for the prostate cancer patient and patient advocacy community: Your Voice in the Future of Active Surveillance, coordinated by Active Surveillance Patients International (ASPI) and AnCan and and supported by many other prostate cancer patient advocacy groups. To register, please click here.
More than 50 percent of all patients currently being diagnosed with prostate cancer are now understood to be appropriate for initial management on active surveillance, without immediate invasive treatments such as surgery or radiation therapy. A significant percentage of those men may never, ever need invasive treatment at all.
Optimizing the accuracy of the diagnosis of such men — and then ensuring high quality monitoring over time (while minimizing the need for unnecessary biopsies) has become a priority for many in the prostate cancer research community who will be participating as speakers and discussants in this informational program. And the patient community has a huge potential role to play in moving these initiatives forward.
Your voice may be critical in moving these initiatives forward over the next three to five years.
Filed under: Uncategorized | 3 Comments »
Posted on December 1, 2021 by Sitemaster
In late October, we had commented on the then-latest revision of the National Comprehensive Cancer Network (NCCN)’s guidelines on the initial management of men with low-risk forms of localized prostate cancer. Specifically we had protested the removal of any suggestion that this form of prostate cancer should — preferably — be managed using active surveillance. The NCCN has now released a new revision to the guidelines that has modified the prior suggestion. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, guidelines, low-risk, NCCN, surveillance | 4 Comments »
Posted on November 30, 2021 by Sitemaster
About 100 patients, clinicians, and others are already registered as attendees at the conference on
Click on the link above for more information and to register. There is still plenty of time to join us.
The conference will take place from 12:00 pm to 4:00 pm Eastern time on Monday, December 13 AND on 12:00 pm to 4:00 pm on Thursday, December 16.
Continue reading →
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Uncategorized | Leave a comment »
Posted on November 12, 2021 by Sitemaster
Registration is now OPEN for the upcoming conference on future research into the use of active surveillance for men with favorable-risk forms of localized prostate cancer:
Click on the link above for more information and to register. … READ MORE …
Filed under: Uncategorized | Leave a comment »
Posted on October 20, 2021 by Sitemaster
As many readers will already be aware, the National Comprehensive Cancer Network (NCCN) has recently removed the word “preferred” from its statement regarding the use of active surveillance (AS) as an appropriate form of management of men with low-risk forms of localized prostate cancer. A broad swath of specialists in the initial management of low-risk disease, as well as many in the patient advocacy community, have been highly critical of this change to the NCCN guidelines. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment, Uncategorized | Tagged: active, guidelines, low-risk, NCCN, surveillance | 10 Comments »
Posted on October 19, 2021 by Sitemaster
Three major randomized clinical trials and a meta-analysis have proved that for most men waiting for early signs of recurrence after prostatectomy (e.g., three consecutive PSA rises or a PSA of 0.1 ng/ml) to give radiation gave the same outcome as immediate (“adjuvant”) radiation (see this link). But there are exceptions. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: adjuvaant, earky, mortality, outcome, post-prostatectomy, risk, salvage | 2 Comments »
Posted on October 17, 2021 by Sitemaster
At the end of September, the Prostate Cancer Foundation appointed Charles {“Chuck”) Ryan, MD — formerly of the University of California, San Francisco, and the University of Minnesota — as the new President and CEO of the Foundation. And there will be two opportunities for patients to hear directly from Dr. Ryan in the near future. … READ MORE …
Filed under: Uncategorized | Leave a comment »
Posted on September 22, 2021 by Sitemaster
Prostate Cancer International (PCaI) is proud to be an inaugural member of the new Prostate Cancer Impact Alliance (PCIA). PCIA’s shared vision is to advance education, research and equitable access to high quality care to better patient outcomes for men with prostate cancer. … READ MORE …
Filed under: Uncategorized | Tagged: advocacy, alliance, outcome, PCIA | 5 Comments »
Posted on September 21, 2021 by Sitemaster
Two educational programs are scheduled on Wednesday, September 29. The two programs will be be very different: one for very early stage patients; the other for patients with progressive prostate cancer at risk for (or already diagnosed with) de novo metastatic, hormone-sensitive prostate cancer (mHSPC) … READ MORE …
Filed under: Uncategorized | Leave a comment »
Posted on August 19, 2021 by Sitemaster
The decision about whether or not to treat the entire pelvic lymph node area along with the prostate (called whole pelvic radiation therapy or WPRT) or to treat just the prostate with a margin around it (called prostate-only radiation therapy or PORT) has long been a matter of judgment. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: outcome, pelvic, prostate-only, radiation, risk | 9 Comments »
Posted on August 19, 2021 by Sitemaster
A new paper by Meissner et al. has reported important, long-term data on fear of recurrence and biochemical progression of prostate cancer among a large cohort of German patients undergoing radical prostatectomy. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: fear, outcome, recurrence, surgery, survey | 3 Comments »
Posted on August 12, 2021 by Sitemaster
For many years your sitemaster has been advising patients that overly early use of androgen deprivation therapy (ADT) in many men with progressive prostate cancer is not necessarily the best decision (for a number of possible reasons). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: ADT, androgen, deprivation, initiation, metastasis., timing | 9 Comments »
Posted on August 11, 2021 by Sitemaster
In 2016, we looked at the Candiolo risk stratification system for radiation therapy. To our knowledge, it has not been prospectively validated or widely adopted. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: nomogram. radiation, predictive, prognosis, risk, stratification, therapy | 4 Comments »
Posted on July 26, 2021 by Sitemaster
As of Friday (July 22), we had received more than 250 responses to our brief survey on research into active surveillance. Most of these are from patients and some from their familial supporters (spouses, partners, etc.). However,we are still interested in getting more input — especially from clinicians, including specialists, generalists, and allied health personnel like urology nurses! … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active surveillance, AS, research | 2 Comments »
Posted on July 26, 2021 by Sitemaster
Three more upcoming webinars this week will deal with (a) the work-up of men with prostate cancer prostate cancer who progress after first-line therapy (such as surgery, radiation, etc.); (b) whether Gleason 6 disease should really be defined as “prostate cancer”; and (c) an update on the most current information related to the evaluation and management of men with prostate cancer appropriate for active surveillance. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: progression. active, surveillance, webinar | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 